MedPath

tDCS for Treatment of Depression in Parkinson's Disease

Not Applicable
Conditions
Idiopathic Parkinson Disease
Depression
Registration Number
NCT02960464
Lead Sponsor
Hospital Santa Marcelina
Brief Summary

Investigation of possible benefits of transcranial direct current stimulation (tDCS) as a treatment of depression in patients with Parkinson's Disease, through a randomized placebo-controlled clinical trial.

Detailed Description

We aim to investigate the effects of transcranial direct current stimulation (tDCS) as treatment for depression in patients with Parkinson's Disease. We have designed a clinical trial in which volunteers that fulfill inclusion criteria will receive 15 sessions of tDCS during 1 week (3 sessions a day, with 30 minutes interval in between). Subjects will be randomly allocated into two groups, one that will receive the real intervention (active) and the other that will receive the placebo intervention (sham). The collaborator in charge of administering the session will not participate in the evaluations, keeping both subjects and evaluators blinded to the nature of the sessions. Subjects will be evaluated at baseline, and after the end of sessions, 1 week, 4 weeks and 8 weeks, the latter being the main outcome.

We aim to enroll 50 subjects, 25 for each arm. The sample size calculation took into consideration previous clinical trials using tDCS for depression in different settings.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
50
Inclusion Criteria
  • Idiopathic Parkinson's Disease
  • Geriatric Depression Scale - 15 higher that 5
  • Major Depression Disorder
Exclusion Criteria
  • CNS disease other than Parkinson's Disease (i.e. epilepsy, stroke)
  • Mental disorder other than depression on anxiety disorder (i.e. bipolar disorder, schizophrenia)
  • Previous neurosurgical intervention (i.e. DBS)
  • Current use of antidepressant drug
  • High suicidality risk
  • Limited capacity of understanding written and spoken Portuguese

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Hamilton Rating Scale for Depression8 weeks
Secondary Outcome Measures
NameTimeMethod
Quantitative EEG8 weeks
Geriatric Depression Scale -158 weeks
Parkinson's Disease Questionnaire - 398 weeks
Mini-Mental State Examination8 weeks
Hamilton Anxiety Rating Scale8 weeks
Montgomery-Åsberg Depression Rating Scale8 weeks
Lille apathy rating scale8 weeks

Trial Locations

Locations (1)

Hospital Santa Marcelina

🇧🇷

Sao Paulo, Brazil

Hospital Santa Marcelina
🇧🇷Sao Paulo, Brazil
Pedro Gordon, MD
Principal Investigator
Maria Sheila Rocha, MD, PhD
Sub Investigator
Jamana Barbosa
Sub Investigator

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.